HTL Biotechnology is a French biotech and a world leader in the development and responsible bioproduction of pharmaceutical-grade biopolymers (Hyaluronic acid, polynucleotides). Used by healthcare companies for the development of treatments in various cutting-edge therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. For over 30 years, HTL Biotechnology has been a driving force behind innovation in the sector, collaborating with research entities and biotech companies to address unmet medical needs (regenerative medicine, drug delivery, etc.) HTL Biotechnology recently reinforced its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc (HTL BII – New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) within a world-class scientific research center. To meet growing global needs for biopolymers, the company has also subsidiaries in Asia and building in the United States, a neuromodulator production unit (HTL BMI – Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, research and development, as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. Our ambition is to consolidate our global leadership and create value for our customers with four priorities: Premium positioning, by guaranteeing a high level of product quality and safety. Innovation, by driving research in the biopolymers sector. International expansion, by placing production and R&D at the service of new markets and customers. Social responsibility, through which we aim to transform the biopolymer sector into a positive, sustainable force. Social media group policy: https://htlbiotech.com/wp-content/uploads/2025/03/charte-reseaux-sociaux.pdf" title="" class="btn" data-container="body" data-html="true" data-id="224127" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="HTL Biotechnology"> 9,858
Location
1 Rue Louis Lumière, 35133 La Selle-en-Luitré, France
La Selle-en-Luitré
France
SIREN
382193985Engaged entities
33Added in Motherbase
5 Mar 2024, 6:43 a.m.Leading the development and production of innovative pharmaceutical-grade biopolymers.
HTL Biotechnology is a French biotech and a world leader in the development and responsible bioproduction of pharmaceutical-grade biopolymers (Hyaluronic acid, polynucleotides). Used by healthcare companies for the development of treatments in various cutting-edge therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology.
For over 30 years, HTL Biotechnology has been a driving force behind innovation in the sector, collaborating with research entities and biotech companies to address unmet medical needs (regenerative medicine, drug delivery, etc.) HTL Biotechnology recently reinforced its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc (HTL BII – New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) within a world-class scientific research center.
To meet growing global needs for biopolymers, the company has also subsidiaries in Asia and building in the United States, a neuromodulator production unit (HTL BMI – Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, research and development, as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide.
Our ambition is to consolidate our global leadership and create value for our customers with four priorities:
Premium positioning, by guaranteeing a high level of product quality and safety.
Innovation, by driving research in the biopolymers sector.
International expansion, by placing production and R&D at the service of new markets and customers.
Social responsibility, through which we aim to transform the biopolymer sector into a positive, sustainable force.
Social media group policy: https://htlbiotech.com/wp-content/uploads/2025/03/charte-reseaux-sociaux.pdf
Leader dans le développement et la production de biopolymères innovants de grade pharmaceutique.
HTL Biotechnology est une biotech française et leader mondial dans le développement et la bioproduction responsable de biopolymères de qualité pharmaceutique (acide hyaluronique, polynucléotides). Ces biopolymères sont utilisés par les entreprises de santé pour le développement de traitements dans divers domaines thérapeutiques de pointe tels que l'ophtalmologie, la dermatologie, l'esthétique médicale et la rhumatologie.
HTL Biotechnology a récemment renforcé sa position de leader mondial dans le développement de biopolymères de qualité pharmaceutique en acquérant, par l'intermédiaire de sa filiale HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), une plateforme de protéines recombinantes dont le produit le plus avancé est le collagène humain recombinant de type III (rhCOL3) au sein d'un centre de recherche scientifique de classe mondiale.
Pour répondre aux besoins mondiaux croissants en biopolymères, l'entreprise possède également des filiales en Asie et construit aux États-Unis une unité de production de neuromodulateurs (HTL BMI - Massachusetts). Historiquement basée à Javené (Bretagne - France), l'entreprise regroupe sur son site des activités de production, d'innovation, de recherche et développement, ainsi que de qualité. HTL Biotechnology emploie près de 300 personnes dans le monde.
Notre ambition est de consolider notre leadership mondial et de créer de la valeur pour nos clients autour de quatre priorités :
Le positionnement premium, en garantissant un haut niveau de qualité et de sécurité des produits.
L'innovation, en stimulant la recherche dans le secteur des biopolymères.
L'expansion internationale, en mettant la production et la R&D au service de nouveaux marchés et clients.
La responsabilité sociale, qui nous permet de transformer le secteur des biopolymères en une force positive et durable.
Pour consulter notre politique de modération des réseaux sociaux :
https://htlbiotech.com/wp-content/uploads/2025/03/charte-reseaux-sociaux.pdf
Home - HTL Biotechnology
Entity | Type | Tweets | Articles | |
---|---|---|---|---|
![]() | Préfecture de la région Bretagne Government Administration | Other 20 Dec 2024 | | |
![]() | Institut Choiseul entertainment, Research Services | Other 20 Dec 2024 | | |
![]() | ALTIOS International International Trade and Development, hrtech, fintech | Other 16 Oct 2024 | | |
![]() | CPHI Events Services | Other 11 Oct 2024 | | |
![]() | Entreprendre Newspaper Publishing | Other 2 Aug 2024 | | |
![]() | TVR la chaîne media, Broadcast Media Production and Distribution, martech | Other 26 Jul 2024 | | |
![]() | Ecole nationale supérieure de Chimie de Rennes Higher Education, greentech | Other 4 Feb 2025 | | |
![]() | CHEMDOC WATER TECHNOLOGIES greentech, Industrial Machinery Manufacturing, cleantech, manufacturing, water management | Other 27 Jun 2024 | | |
![]() | L'Usine Nouvelle Newspaper Publishing | Other 10 Jun 2024 | | |
![]() | EY Ventury Avocats Law Practice | Other 13 Jun 2024 | |